| 1.12 -0.05 (-4.27%) | 12-31 19:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.54 | 1-year : | 1.69 |
| Resists | First : | 1.32 | Second : | 1.45 |
| Pivot price | 1.25  |
|||
| Supports | First : | 1.11 | Second : | 0.92 |
| MAs | MA(5) : | 1.12 |
MA(20) : | 1.27 |
| MA(100) : | 1.56 |
MA(250) : | 2.61 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 2.8 | D(3) : | 2.8 |
| RSI | RSI(14): 39.7 | |||
| 52-week | High : | 4.96 | Low : | 0.85 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ODT ] has closed above bottom band by 20.2%. Bollinger Bands are 34.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
Thu, 28 Sep 2023
Orally Disintegrating Tablet (ODT) Market Analysis, Size, Current Scenario and Future Prospects - openPR
Tue, 27 Apr 2021
Odonate Therapeutics: Lessons Learned (NASDAQ:ODT) - Seeking Alpha
Wed, 24 Mar 2021
Do Options Traders Know Something About Odonate Therapeutics (ODT) Stock We Don't? - Yahoo Movies UK
Mon, 22 Mar 2021
Odonate Therapeutics Announces Discontinuation of Development of Tesetaxel - Business Wire
Fri, 28 Aug 2020
The Daily Biotech Pulse: Moderna Japanese Vaccine Deal Talk, Lipocine FDA Decision, Liver Congress Presentations - Yahoo Finance
Wed, 26 Jun 2019
Odonate Therapeutics: Making Taxanes Orally Available (OTCMKTS:ODTCD) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 38 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 65.6 (%) |
| Shares Short | 380 (K) |
| Shares Short P.Month | 513 (K) |
| EPS | -2.72 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.85 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -33.1 % |
| Return on Equity (ttm) | -86.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -95 (M) |
| Levered Free Cash Flow | -44 (M) |
| PE Ratio | -0.42 |
| PEG Ratio | 0 |
| Price to Book value | 0.6 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|